RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Intra-Cellular Therapies (NASDAQ:ITCI), but lowered the price target from $77 to $76.

November 03, 2023 | 6:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Intra-Cellular Therapies but lowered the price target from $77 to $76.
The news is directly related to Intra-Cellular Therapies (ITCI). While the 'Outperform' rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact is likely to be neutral as the decrease in the price target is minimal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100